An interventional study of FlowOx in Periferal Arterial Occlusive Disease, PAOD, sponsored by Otivio AS. Status unknown at 1 site in Norway. Open to participants aged 30 Years to 90 Years. Per ClinicalTrials.gov, last updated 2013-10-31.
Sponsored by Otivio AS · Not applicable and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to assess the effect of negative pulsating pressure therapy on patients with impaired blood flow to the leg caused by arterial disease, to see if the FlowOx device will increase the blood flow to the leg in these patients.
230 studies on the registry are indexed under Arterial Occlusive Diseases; 27 are open to participants now.
This study's planned enrollment of 20 is below the median of 184 across 157 interventional studies indexed under Arterial Occlusive Diseases.
Browse Arterial Occlusive Diseases studies →Otivio AS is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with Peripheral Arterial Occlusive Disease (PAOD) grade 2,3 or 4, i.e.:
Clinically verified grade 2, i.e. Intermittent Claudication:
Clinically verified grade 3, i.e. Critical Limb Ischemia (CLI):
Clinically verified grade 4, i.e. CLI:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg
Device: FlowOx
Boot-shaped pressure chamber generating pulsating negative pressure
% of the prescribed cycles delivered in the specified time FlowOx™-induced change in arterial leg blood flow (LBF)
This is calculated as the difference between the blood flow during the period using FlowOx™ (middle value over a period of 5 minutes) and baseline blood flow (middle value over a period of 5 prior to using FlowOx™)
Time frame: up to 1 hour
Patient comfort measured by asking the patient a fixed set of questions
Time frame: up to 1 hour
Fitting time
Time frame: up to 1 hour
The record gives a start of Aug 2013, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otivio AS